293 related articles for article (PubMed ID: 32019190)
1. Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy.
Sircar A; Chowdhury SM; Hart A; Bell WC; Singh S; Sehgal L; Epperla N
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019190
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic significance of monoclonal small cells in the peripheral blood and bone marrow of various B-cell lymphomas.
Nakano M; Kawanishi Y; Kuge S; Kuriyama Y; Kuwabara S; Yaguchi M; Toyama K
Blood; 1992 Jun; 79(12):3253-60. PubMed ID: 1375848
[TBL] [Abstract][Full Text] [Related]
4. Aggressive B-cell lymphomas with a primary bone marrow presentation.
Zamò A; Johnston P; Attygalle AD; Laurent C; Arber DA; Fend F
Histopathology; 2020 Sep; 77(3):369-379. PubMed ID: 32324290
[TBL] [Abstract][Full Text] [Related]
5. Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms.
Dumontet E; Mancini SJC; Tarte K
Front Immunol; 2021; 12():784691. PubMed ID: 34956214
[TBL] [Abstract][Full Text] [Related]
6. Lymphoblastic lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
[TBL] [Abstract][Full Text] [Related]
7. The challenge of the microenvironment in B-cell lymphomas.
Coupland SE
Histopathology; 2011 Jan; 58(1):69-80. PubMed ID: 21261684
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL).
Perea G; Altés A; Bellido M; Aventín A; Bordes R; Ayats R; Remacha AF; Espinosa I; Briones J; Sierra J; Nomdedéu JF
Histopathology; 2004 Sep; 45(3):268-74. PubMed ID: 15330805
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Gribben JG; Fowler N; Morschhauser F
J Clin Oncol; 2015 Sep; 33(25):2803-11. PubMed ID: 26195701
[TBL] [Abstract][Full Text] [Related]
11. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
12. Use of CD137 ligand expression in the detection of small B-cell lymphomas involving the bone marrow.
Zhao S; Xing Y; Natkunam Y
Hum Pathol; 2014 May; 45(5):1024-30. PubMed ID: 24746207
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas.
Palacio C; Acebedo G; Navarrete M; Ruiz-Marcellán C; Sanchez C; Blanco A; López A
Haematologica; 2001 Sep; 86(9):934-40. PubMed ID: 11532621
[TBL] [Abstract][Full Text] [Related]
14. [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].
Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Ma XL; Zhang YH
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):748-753. PubMed ID: 29050112
[No Abstract] [Full Text] [Related]
15. The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors.
Menter T; Tzankov A; Dirnhofer S
Hematol Oncol; 2021 Feb; 39(1):3-10. PubMed ID: 33105031
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA Expression Profile in Bone Marrow and Lymph Nodes in B-Cell Lymphomas.
Veryaskina YA; Titov SE; Kovynev IB; Pospelova TI; Fyodorova SS; Shebunyaeva YY; Sumenkova DV; Zhimulev IF
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894763
[TBL] [Abstract][Full Text] [Related]
17. De novo acute B cell leukemia/lymphoma with t(14;18).
Stamatoullas A; Buchonnet G; Lepretre S; Lenain P; Lenormand B; Duval C; Callat MP; Gaulard P; Bastard C; Tilly H
Leukemia; 2000 Nov; 14(11):1960-6. PubMed ID: 11069032
[TBL] [Abstract][Full Text] [Related]
18. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
19. A subset of CD45+/CD19 - cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma.
Kim SM; Lee ST; Ryu KJ; Kim HJ; Kim SH; Ko YH; Kim WS; Kim SJ
Leuk Lymphoma; 2015; 56(11):3052-7. PubMed ID: 25739938
[TBL] [Abstract][Full Text] [Related]
20. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index.
Chung R; Lai R; Wei P; Lee J; Hanson J; Belch AR; Turner AR; Reiman T
Blood; 2007 Aug; 110(4):1278-82. PubMed ID: 17475910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
